Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Burkitt Lymphoma 22Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7Lymphoma 5Recurrence 4Lymphoma, Large B-Cell, Diffuse 4Leukemia 3Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Philadelphia Chromosome 1Lymphoma, Follicular 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Inotuzumab Ozogamicin × Lymphoid × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡